Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUTO CAR T cell therapy · 1 trial · 5 indications
Monitoring of all SAEs / AESIs, including any new malignancy or new diagnosis of neurologic disorders, or other hematologic disorder, related to AUTO CAR T cell therapy. Monitoring of all adverse events of special interest related to AUTO CAR T cell therapy infusion.
| Arm | Type | Description |
|---|---|---|
| AUTO CAR T cell therapy | EXPERIMENTAL | Patients who received previous treatment with AUTO CAR T Cell Therapy |
| Name | Type | Description |
|---|---|---|
| AUTO CAR T cell therapy | BIOLOGICAL | No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion. |
Inclusion Criteria: 1. Patients must have received an AUTO CAR T cell therapy on a clinical treatment study. 2. Patients must have provided informed consent for long-term follow-up study prior to participation. 3. Patients must be able to comply with the study requirements. Exclusion Criteria: 1....
AUTO CAR T cell therapy is a genetically modified autologous T cell treatment being studied in oncology. It is used in a long-term follow-up study for patients with multiple myeloma, diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL) in adults and children, and T cell lymphoma. The study follows patients for up to 15 years after their first dose.
AUTO CAR T cell therapy is being developed by Autolus Therapeutics plc, a biopharmaceutical company traded on the stock exchange under the ticker symbol AUTL. The company is conducting a Phase 2 clinical trial to evaluate the long-term safety and outcomes of this genetically modified cell therapy in patients with certain blood cancers.
AUTO CAR T cell therapy is in Phase 2 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The current Phase 2 trial is a long-term follow-up study designed to monitor patients for up to 15 years after their first dose of the therapy.
AUTO CAR T cell therapy is being studied in one clinical trial registered as NCT03628612, titled "Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells." This Phase 2 trial is enrolling by invitation and aims to enroll 500 participants across the United States and United Kingdom. The study is uncontrolled and not blinded.
AUTO CAR T cell therapy works by using genetically modified autologous T cells, which are a patient's own immune cells that have been engineered to recognize and attack cancer cells. This approach is designed to target and destroy malignant cells in conditions such as multiple myeloma, DLBCL, ALL, and T cell lymphoma.